Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by burrowsjon Jan 15, 2009 9:45am
862 Views
Post# 15705997

RE: RE: RE: Too Quiet

RE: RE: RE: Too Quiet"but we doubt DM's word and ability to deliver on his very large promises"  3wood, how could anyone who knows the story and players involved disagree.  There has been a history of over promise and under deliver.

DM and his crew flew back Tuesday night from San Fran.  They were at the JP Morgan bio-conference held at the Westin St. Francis.  I am to understand that all four pharmas are still negotiating.  I also understand that the third arm of 1b/2a has begun or is to begin shortly.  The financial position of the company is no secret.  I think in the next three too four weeks we will hear good news that takes out the debenture holders (my conjecture).  I do think that in the next three to four weeks we will hear good news regardless of it being science related or a one country license deal or better.

As for the $10, you should see that or better before IVUS in July.  I wouldn't sell anything for at least the next four weeks. 
Bullboard Posts